APP transgenic mice: the effect of active and passive immunotherapy in cognitive tasks.
Various immunotherapy strategies for APP transgenic mice have emerged in recent years. Specifically, active immunization with beta-amyloid (A beta) or passive immunization with anti-A beta-antibodies in APP transgenic mice has appeared most promising. Recent studies have shown that treatment of APP transgenic mice either with A beta(40/42) or A beta-specific antibodies can have beneficial effects in cognitive tasks. Active as well as passive immunization have been shown to affect spatial, non-spatial, emotional and object-related learning and memory. Such effects can be observed when treatments are applied prophylactically (before apparent A beta pathology) or therapeutically (after the development of A beta pathology) in APP transgenic mice. This review focuses on such cognitive outcomes of different active and passive immunization strategies in APP transgenic mice.
Department of Neurology, Research Group for Neurological Therapeutics, Biomedical Research Centre, Philipps-University Marburg, Hans-Meerwein-Strasse, 35043 Marburg, Germany.
Stephan
S
Röskam
Frauke
F
Neff
Rainer
R
Schwarting
Michael
M
Bacher
Richard
R
Dodel
D000544:Alzheimer Disease / Q000628:therapy*; D016229:Amyloid beta-Peptides / Q000235:genetics / Q000276:immunology; D016564:Amyloid beta-Protein Precursor / Q000235:genetics*; D000818:Animals; D003072:Cognition Disorders / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D016233:Immunotherapy, Active / Q000379:methods*; D051379:Mice; D008822:Mice, Transgenic; D009483:Neuropsychological Tests; D058255:Protease Nexins; D011956:Receptors, Cell Surface / Q000235:genetics*
C545487:APP protein, human; D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D058255:Protease Nexins; D011956:Receptors, Cell Surface